India’s Pharma Exports Cross US$ 30B in FY25
India’s pharmaceutical exports achieved a record-breaking milestone, exceeding US$ 30 billion for the first time in FY25, which was strongly driven by demand from the United States and several key global markets. The sector reached US$ 30.47 billion during FY25 while demonstrating a yearly growth of 9.4 percent as compared to US$ 27.85 billion in FY24. The monthly export rate in March registered a 30 percent annual growth, reaching US$ 3.68 billion.
United States retained its position as India’s leading pharmaceutical importer, as it acquired US$ 8.95 billion worth of medicines during the period, which exhibited a 14.29 percent annual increase. Other major pharmaceutical markets included UK, Brazil, France, and South Africa. Industry experts point to India’s expanding global role in generics manufacturing. According to McKinsey & Company, a global management consulting firm, India holds the title as the globe’s largest generic drug supplier while experiencing a 9 percent annual export growth rate, which exceeds global averages by nearly double.
The pharmaceutical sector is expected to continue growing in the upcoming years. India Ratings and Research (Ind-Ra), which provides India’s credit markets with credible opinions, anticipates the domestic pharmaceutical industry to expand at an 8-9 percent rate during FY26 owing to strong pricing strategies, innovative markets, and constant customer demand. Growth during FY25 occurred mainly through two factors: price increases totaling 5.5 percent and 2.7 percent coming from new product introductions; while sales volume remained flat.
Pharma sales in February 2025 showed a 7.5 percent growth compared to last year’s numbers due to their effective pricing strategies and robust product pipelines. India’s pharmaceutical sector maintains its role as a leading global pharmaceutical supplier because of its 8 percent compound annual growth rate and export strength, fueling global healthcare accessibility while boosting the national economy.